Recap: Intra-Cellular Therapies Q2 Earnings

Shares of Intra-Cellular Therapies ITCI fell 2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 41.18% year over year to ($0.96), which missed the estimate of ($0.91).

Revenue of $1,907,000 higher by 0.00% from the same period last year, which missed the estimate of $3,030,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Aug 10, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/wen7vxux

Recent Stock Performance

52-week high: $43.56

52-week low: $6.75

Price action over last quarter: Up 7.13%

Company Overview

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.